ReviewNPJ Parkinson's disease2026
Primary prevention of Parkinson's disease: proceedings, the 8C's and a position statement from the Parkinson's disease prevention think tank.
Review in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This Perspective outlines the challenges addressed at the first Annual Parkinson's Disease (PD) Prevention Think Tank, held on November 20-21, 2025 in Gainesville, Florida at the Fixel Institute. Over the course of two days, attendees from a wide variety of disciplines, including movement disorders neurology, environmental sciences, agriculture, public policy, public health, patient advocate groups, and more, discussed the current state of primary prevention research in PD, examined the lessons learned from prevention research in other disorders, and identified necessary regulatory and policy actions for moving toward primary prevention of PD. Eight key components of primary prevention are identified (8 C's): accurately Count incidence and prevalence, Conduct longitudinal cohort studies, induce policy Change, Counsel on individual behavior change, Communicate clearly with the general public and with key stakeholders, form multi-centric Coalitions across neurodegenerative disorders, apply Cross-disciplinary approaches, and provide sustained financial Commitment to support ongoing prevention and mitigation efforts. These proceedings serve as an initial call-to-action for at-risk individuals, the clinicians who care for them, and for policymakers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.